INSULIN BIOSIMILARS MARKET ANALYSIS

Insulin Biosimilars Market, by Biosimilar Type (Rapid-acting Biosimilars, Long-acting Biosimilars, and Premixed Biosimilars), by Disease Indication Type (Type 1 Diabetes and Type 2 Diabetes), and by Geography - Size, Share, Outlook and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI1750
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Insulin Biosimilars Market – Competitive Insights

The key players operating in the global insulin biosimilars market includes Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A., Ypsomed AG and others Key players are engaged in developing new technologies and collaborations in order to retain dominant position in the market. For instance on 2018 Sandoz, a Norartis division and Asia’s premier biopharmaceutical company, Biocon announced exclusive global collaboration for next generation biosimilars.